Actionable news
All posts from Actionable news

AKTX Falls To Disgrace, CATB Awaits Data In Q3, CORI Surges On Trial Data

( - Today's Daily Dose brings you news about Akari's CEO fall into disgrace; Cancer Genetics' Q1 financial results, Corium's encouraging results from its pilot bioequivalence study and the upcoming catalyst of Catabasis.

Read on.

Shares of Akari Therapeutics Plc ( AKTX ) plunged over 19% in extended trading on Thursday after the Company announced that its CEO Gur Roshwalb has been placed on administrative leave.

On April 27, 2017, Edison withdrew the report stating that there were material errors in it, and also suspended coverage of Akari Therapeutics.

Coversin, Akari's lead drug candidate, is a next-generation C5 inhibitor, and is derived from the saliva of the Ornithodoros moubata tick.

Coversin's potential is being explored in the indications of paroxysmal nocturnal haemoglobinuria (PNH), atypical Hemolytic Uremic Syndrome (aHUS), and Guillain Barré syndrome (GBS).

Coversin is under two phase II clinical trials in the indication of paroxysmal nocturnal haemoglobinuria.

Soliris is the first and only approved C5 inhibitor to treat patients with PNH and atypical hemolytic uremic syndrome.

AKTX closed Thursday's trading at $11.49, up 4.45%. In after-hours, the stock fell 19.93% to $9.20.

Cancer Genetics Inc. ( CGIX ) has reported a 15% revenue growth in its first quarter of 2017 and a 16% decline in adjusted net loss over the comparable year-ago period.

On a non-GAAP basis, the net loss for the first quarter of 2017, narrowed to $2.1 million or $0.11 per share from $5.3 million or $0.39 per share in Q1 2016. Total...